Cantor Fitzgerald Reiterates Overweight Rating on MannKind (MNKD)

Cantor Fitzgerald analyst Brandon Folkes reiterated an Overweight rating and $3.00 price target on MannKind (NASDAQ: MNKD) following results.

The analyst commented, "MNKD has successfully developed Afrezza, an inhaled insulin, which offers a unique delivery proposition, within a very large market opportunity. Initial expectations for Afrezza turned out to be unrealistic; however, we believe expectations have been adequately reset to more reasonable and attainable levels, which should allow MNKD stock to reward new investors. To date, since receiving Afrezza back from SNY (NC), the co. has made good strides to drive growth in the product. Thus, we believe that upwards earnings revisions and pipeline advancements should drive its stock higher. We believe majority of the value in MNKD stock will still be driven by Afrezza; however, we view the pipeline as offering a number of potential call options for investors over time."

For an analyst ratings summary and ratings history on MannKind click here. For more ratings news on MannKind click here.

Shares of MannKind closed at $1.49 yesterday.

You May Also Be Interested In

• MannKind Announces $50 Million Private Placement
• T-Mobile (TMUS) PT Lowered to $280 at Benchmark, Buy Rating Maintained
• Intel (INTC) PT Lowered to $125 at Cantor Fitzgerald on Cloudy Picture for Client, Share Losses